Duobrii (halobetasol propionate and tazarotene)

pCPA File Number: 21312
Negotiation Status:
Concluded with an LOI
Indication(s):
Psoriasis, moderate to severe plaque
Sponsor/Manufacturer:
Bausch Health, Canada Inc.
CDA-AMC Project Number:
SR0638-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: